Therapeutic application of botulinum toxin

References

1. Simpson LC. The origin, structure and pharmacological activity of botulinum toxin. Pharmacol Rev 1981; 33:155–188
   [Google Scholar]
2. Tacket CO, Ragowski MA. Botulism. In: Simpson LC. (ed) Botulinum neurotoxin and tetanus toxin New York: Academic Press; 1989351–378
   [Google Scholar]
3. MacDonald KL, Cohen ML, Blake PA. The changing epidemiology of adult botulism in the United States. Am J Epidemiol 1986; 124:794–799
   [Google Scholar]
4. MacDonald KL, Rutherford GW, Friedman SM et al. Botulism and botulism-like illness in chronic drug abusers. Ann Intern Med 1985; 102:616–618
   [Google Scholar]
5. Stephen J, Pietrowski RA. Bacterial toxins. Walton-on-Thames, Nelson; 19811–8
   [Google Scholar]
6. Arnon SS. Infant botulism. In: Boriello SP. (ed) Clinical and molecular aspects of anaerobes Petersfield: Wrightson Biomedical Publishing Ltd.; 199041–48
   [Google Scholar]
7. Burgen ASV, Dickens F, Zatman LJ. The action of botulinum toxin on the neuromuscular junction. J Phvsiol 1949; 109:10–24
   [Google Scholar]
8. Shone CC, Hambleton P. Toxigenic Clostridia. In: Minton NP, Clarke DJ. (eds) Clostridia New York: Plenum Press; 1989265–292
   [Google Scholar]
9. Niemann H. Molecular biology of clostridial neurotoxins. In: Sourcebook of bacterial protein toxins London: Academic Press; 1991303–348
   [Google Scholar]
10. Harris AJ, Miledi R. The effect of type D botulinum toxin on frog neuromuscular junctions. J Physiol 1971; 217:497–515
    [Google Scholar]
11. Dreyer F, Mallart A, Brigant JL. Botulinum A toxin and tetanus toxin do not affect presynaptic membrane currents in mammalian motor nerve endings. Brain Res 1983; 270:373–375
    [Google Scholar]
12. Dolly JO, Black J, Williams RS, Melling J. Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalisation. Nature 1984; 307:457–460
    [Google Scholar]
13. Simpson LC. Peripheral actions of the botulinum toxins. In: Simpson LC. (ed) Botulinum neurotoxin and tetanus toxin New York: Academic Press; 1989153–178
    [Google Scholar]
14. de Paiva A, Dolly JO. Light chain of botulinum neurotoxin is active in mammalian nerve terminals when delivered via liposomes. FEBS Lett 1990; 277:171–174
    [Google Scholar]
15. Shone CC, Hambleton P, Melling J. Inactivation of Clostridium botulinum type A neurotoxin by trypsin and purification of two tryptic fragments. Proteolytic action near the COOH-terminus of the heavy subunit destroys toxin-binding activity. Eur JBiochem 1985; 151:75–82
    [Google Scholar]
16. Kozaki S, Ogasawara J, Shimote Y, Kamata Y, Sakaguchi G. Antigenic structure of Clostridium botulinum type B neurotoxin and its interaction with gangliosides, cerebrosides and free fatty acids. Infect Immun 1987; 55:3051–3056
    [Google Scholar]
17. Shone CC, Hambleton P, Melling J. A 50-kDa fragment from the NH₂-terminus of the heavy subunit of Clostridium botulinum type A neurotoxin forms channels in lipid vesicles. Eur J Biochem 1987; 167:175–180
    [Google Scholar]
18. Schiavo G, Rossetto O, Santucci A, DasGupta BR, Montecucco C. Botulinum neurotoxins are zinc proteins. J Biol Chem 1992; 267:23479–23483
    [Google Scholar]
19. Schiavo G, Benfenati F, Poulain B et al. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992; 359:832–835
    [Google Scholar]
20. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980; 87:1044–1049
    [Google Scholar]
21. Marsden CD, Quinn NP. The dystonias Neurological disorders affecting 20 000 people in Britain. BMJ 1990; 300:139–144
    [Google Scholar]
22. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. New Engl J Med 1991; 324:1186–1194
    [Google Scholar]
23. Elston JS. Botulinum toxin treatment of blepharospasm. Adv Neurol 1988; 50:579–581
    [Google Scholar]
24. Tsui JKC, Eisen A, Stoessl AJ, Caine S, Caine DB. Double blind study of botulinum toxin in spasmodic torticollis. Neurology 1986; 40:1213–1218
    [Google Scholar]
25. Hambleton P, Cohen HE, Palmer BJ, Melling J. Antitoxins and botulinum toxin treatment. BMJ 1992; 304:959–960
    [Google Scholar]
26. Ludlow CL, Hallet M, Rhew K et al. Therapeutic use of type F botulinum toxin. N Engl J Med 1992; 326:349–350
    [Google Scholar]